Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04434261

Acronym

ASTANA

Enrollment

1500

Registered

2020-06-16

Start date

2020-05-11

Completion date

2021-09-30

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology, SARS-CoV-2, Surgery

Keywords

SARS-CoV-2, Surgical Oncology, PT-PCR Screening Test

Brief summary

To evaluate the incidence of patients with a positive test for SARS-CoV-2, performed in the preoperative screening for patients treated at the institution

Detailed description

Cohort, prospective, observational study to evaluate the incidence of asymptomatic patients with a positive SARS-CoV-2 test detected in the preoperative screening program of the institution.

Interventions

DIAGNOSTIC_TESTPT-PCR test for SARS-CoV-2

Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients with elective surgery scheduled at the IBCC, including those diagnosed with any type of cancer; * Patients who will undergo the screening test for SARS-COV-2 by RT-PCR (nasal swab), according to the guidelines and protocol of the hospital

Exclusion criteria

* Urgent or emergency surgery; * Screening test for SARS-COV-2 not performed * Incomplete data in the institutional database

Design outcomes

Primary

Measure	Time frame	Description
Incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program	May- December 2020	Describe the incidence of patients with a positive test for SARS-CoV-2, detected in the preoperative screening program in our center

Secondary

Measure	Time frame	Description
Incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test;	Up to 30 days	Describe the incidence of SARS-CoV-2 infection in the postoperative period in patients with negative screening test.
Postoperative complications	Up to 30 days	Postoperative complications will be recorded, according to the Clavien-Dindo classification.
Mortality	30 days	To evaluate the risk of all-cause mortality
Delay in the cancer treatment	May 2020- March 2021	Assess the impact of delayed cancer treatment

Countries

Brazil

Contacts

Primary ContactAndre Lopes, MD

andrelopes1002@hotmail.com+551134744242

Backup ContactAlayne Yamada, PhD

alayne.pesquisa@ibcc-mooca.org.br+551134744242

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026